194 related articles for article (PubMed ID: 23226463)
1. Hsp40 gene therapy exerts therapeutic effects on polyglutamine disease mice via a non-cell autonomous mechanism.
Popiel HA; Takeuchi T; Fujita H; Yamamoto K; Ito C; Yamane H; Muramatsu S; Toda T; Wada K; Nagai Y
PLoS One; 2012; 7(11):e51069. PubMed ID: 23226463
[TBL] [Abstract][Full Text] [Related]
2. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice.
Popiel HA; Nagai Y; Fujikake N; Toda T
Neurosci Lett; 2009 Jan; 449(2):87-92. PubMed ID: 18603372
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
[TBL] [Abstract][Full Text] [Related]
4. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo.
Popiel HA; Nagai Y; Fujikake N; Toda T
Mol Ther; 2007 Feb; 15(2):303-9. PubMed ID: 17235308
[TBL] [Abstract][Full Text] [Related]
5. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
Nagai Y; Nukina N
Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease.
Tomás-Zapico C; Díez-Zaera M; Ferrer I; Gómez-Ramos P; Morán MA; Miras-Portugal MT; Díaz-Hernández M; Lucas JJ
Hum Mol Genet; 2012 Feb; 21(3):495-510. PubMed ID: 22045698
[TBL] [Abstract][Full Text] [Related]
7. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
[TBL] [Abstract][Full Text] [Related]
8. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein.
Bauer PO; Goswami A; Wong HK; Okuno M; Kurosawa M; Yamada M; Miyazaki H; Matsumoto G; Kino Y; Nagai Y; Nukina N
Nat Biotechnol; 2010 Mar; 28(3):256-63. PubMed ID: 20190739
[TBL] [Abstract][Full Text] [Related]
9. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones.
Fujikake N; Nagai Y; Popiel HA; Okamoto Y; Yamaguchi M; Toda T
J Biol Chem; 2008 Sep; 283(38):26188-97. PubMed ID: 18632670
[TBL] [Abstract][Full Text] [Related]
10. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.
Zhang X; Smith DL; Meriin AB; Engemann S; Russel DE; Roark M; Washington SL; Maxwell MM; Marsh JL; Thompson LM; Wanker EE; Young AB; Housman DE; Bates GP; Sherman MY; Kazantsev AG
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):892-7. PubMed ID: 15642944
[TBL] [Abstract][Full Text] [Related]
11. Suppression of protein aggregation by chaperone modification of high molecular weight complexes.
Labbadia J; Novoselov SS; Bett JS; Weiss A; Paganetti P; Bates GP; Cheetham ME
Brain; 2012 Apr; 135(Pt 4):1180-96. PubMed ID: 22396390
[TBL] [Abstract][Full Text] [Related]
12. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
Nagai Y
Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
[TBL] [Abstract][Full Text] [Related]
13. A huntingtin peptide inhibits polyQ-huntingtin associated defects.
Arribat Y; Bonneaud N; Talmat-Amar Y; Layalle S; Parmentier ML; Maschat F
PLoS One; 2013; 8(7):e68775. PubMed ID: 23861941
[TBL] [Abstract][Full Text] [Related]
14. Astrocytic expression of the chaperone DNAJB6 results in non-cell autonomous protection in Huntington's disease.
Bason M; Meister-Broekema M; Alberts N; Dijkers P; Bergink S; Sibon OCM; Kampinga HH
Neurobiol Dis; 2019 Apr; 124():108-117. PubMed ID: 30408590
[TBL] [Abstract][Full Text] [Related]
15. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.
Jana NR; Tanaka M; Wang Gh; Nukina N
Hum Mol Genet; 2000 Aug; 9(13):2009-18. PubMed ID: 10942430
[TBL] [Abstract][Full Text] [Related]
16. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
Nagai Y; Fujikake N; Popiel HA; Wada K
Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
[TBL] [Abstract][Full Text] [Related]
17. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.
van Dellen A; Cordery PM; Spires TL; Blakemore C; Hannan AJ
BMC Neurosci; 2008 Apr; 9():34. PubMed ID: 18380890
[TBL] [Abstract][Full Text] [Related]
18. The DNAJB6 and DNAJB8 protein chaperones prevent intracellular aggregation of polyglutamine peptides.
Gillis J; Schipper-Krom S; Juenemann K; Gruber A; Coolen S; van den Nieuwendijk R; van Veen H; Overkleeft H; Goedhart J; Kampinga HH; Reits EA
J Biol Chem; 2013 Jun; 288(24):17225-37. PubMed ID: 23612975
[TBL] [Abstract][Full Text] [Related]
19. The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.
Popiel HA; Burke JR; Strittmatter WJ; Oishi S; Fujii N; Takeuchi T; Toda T; Wada K; Nagai Y
J Amino Acids; 2011; 2011():265084. PubMed ID: 22312459
[TBL] [Abstract][Full Text] [Related]
20. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease.
Howarth JL; Kelly S; Keasey MP; Glover CP; Lee YB; Mitrophanous K; Chapple JP; Gallo JM; Cheetham ME; Uney JB
Mol Ther; 2007 Jun; 15(6):1100-5. PubMed ID: 17426712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
